

Additional file 1. Proportion of patients with significant mean SLN immune cell density in groups with different patient and tumor characteristics

	Patient no.	FOXP3 (>1900 cells/mm ²)		OX40 (>73 cells/mm ²)		CD123 (>480 cells/mm ²)		DC-LAMP (>936 cells/mm ²)	
		No. (%)	P	No. (%)	P	No. (%)	P	No. (%)	P
All patients	60	33 (55)		34 (58)		34 (58)		30 (50)	
Age									
<53 years	30	15 (50)		18 (60)		21 (72)		13 (43)	
>53 years	30	18 (60)	n.s.	16 (55)	n.s.	13 (43)	0.0238	17 (57)	n.s.
Sex									
Male	27	17 (63)		18 (69)		14 (52)		15 (56)	
Female	33	16 (48)	n.s.	16 (48)	n.s.	20 (62)	n.s.	15 (45)	n.s.
Location									
Extremities	31	18 (58)		20 (65)		16 (52)		13 (42)	
Trunk	29	15 (52)	n.s.	14 (50)	n.s.	18 (64)	n.s.	17 (59)	n.s.
Type¹									
SSM	37	19 (51)		22 (61)		21 (58)		19 (51)	
NM	19	10 (53)	n.s.	9 (47)	n.s.	13 (68)	n.s.	11 (58)	n.s.
Thickness (mm)									
1.01-2.0	29	14 (48)		13 (46)		16 (57)		15 (52)	
2.01-4.0	20	11 (55)		14 (70)		13 (65)		8 (40)	
>4.0	11	8 (73)	n.s.	7 (64)	n.s.	5 (45)	n.s.	7 (64)	n.s.
Ulceration¹									
Absent	37	19 (51)		18 (50)		21 (58)		20 (54)	
Present	20	12 (60)	n.s.	13 (65)	n.s.	12 (60)	n.s.	10 (50)	n.s.
SLN status									
Negative	35	18 (51)		19 (54)		19 (56)		16 (46)	
Positive	25	15 (60)	n.s.	15 (62)	n.s.	15 (60)	n.s.	14 (56)	n.s.

¹ALM (n=4) cases, and 3 cases with ulceration unknown are not shown; n.s., not significant; SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral lentiginous melanoma